#1 Clinical Trials Search in Europe

Casirivimab

This article examines the use of casirivimab, a monoclonal antibody, in clinical trials for the treatment and prevention of COVID-19. Casirivimab is often used in combination with imdevimab as part of antibody cocktails designed to target the SARS-CoV-2 virus. The trials discussed here evaluate the safety, efficacy, and optimal dosing of casirivimab-containing treatments in various patient populations, from mild cases to critically ill individuals, as well as its potential for preventing infection in high-risk groups.

Table of Contents

What is Casirivimab?

Casirivimab is a monoclonal antibody medication developed to treat COVID-19. It is typically used in combination with another monoclonal antibody called imdevimab. Together, they are known by several names, including:

  • REGN-COV2
  • REGEN-COV™
  • Ronapreve™
  • REGN10933 (for casirivimab) + REGN10987 (for imdevimab)
Monoclonal antibodies are laboratory-made proteins that mimic the immune system’s ability to fight off harmful pathogens such as viruses.[1]

How Casirivimab Works

Casirivimab works by targeting the spike protein of the SARS-CoV-2 virus, which causes COVID-19. By attaching to this protein, it helps prevent the virus from entering human cells and replicating. When used in combination with imdevimab, the two antibodies work together to provide a more robust defense against the virus.[1]

Conditions Treated

Casirivimab, in combination with imdevimab, is primarily used to treat:

  • Mild to moderate COVID-19 in non-hospitalized patients who are at high risk of progressing to severe disease
  • Prevention of COVID-19 in certain high-risk individuals who have been exposed to the virus
It’s important to note that this treatment is not typically used for patients who are already hospitalized due to severe COVID-19.[1] [2]

Administration

Casirivimab and imdevimab can be administered in several ways:

  • Intravenous (IV) infusion: The medication is given directly into a vein over a period of time, usually about an hour.
  • Subcutaneous (SC) injection: The medication is injected under the skin.
The method of administration and dosage may vary depending on the specific situation and the patient’s condition.[1] [3]

Efficacy

Clinical trials have shown that casirivimab, when used with imdevimab, can be effective in:

  • Reducing viral load (the amount of virus in a person’s body)
  • Shortening the duration of COVID-19 symptoms
  • Reducing the risk of hospitalization or death in high-risk patients with mild to moderate COVID-19
  • Potentially preventing COVID-19 in exposed individuals
However, it’s important to note that the effectiveness can vary depending on factors such as the specific variant of the virus and the timing of treatment.[1] [2]

Safety and Side Effects

While casirivimab and imdevimab are generally considered safe, they can cause side effects. Common side effects may include:

  • Injection site reactions (pain, redness, or swelling where the medication was injected)
  • Infusion-related reactions (if given intravenously)
  • Hypersensitivity reactions (allergic reactions)
Severe side effects are rare but can occur. Patients should be monitored during and after administration of the medication.[1] [3]

Ongoing Research

Research on casirivimab and imdevimab is ongoing. Current studies are investigating:

  • The effectiveness of different dosages and administration methods
  • Use in specific populations, such as immunocompromised individuals or children
  • Potential interactions with COVID-19 vaccines
  • Effectiveness against new variants of the virus
These ongoing studies will help to further refine the use of this treatment in the fight against COVID-19.[3] [4]

Aspect Details
Main uses of casirivimab in trials Treatment of mild to moderate COVID-19, prevention in high-risk individuals, management of critically ill patients
Common combination Often used with imdevimab (REGN-COV2, REGEN-COV™, Ronapreve™)
Administration methods Intravenous (IV) infusion, subcutaneous (SC) injection
Key patient populations Adults, children, immunocompromised individuals, pregnant women, organ transplant recipients
Primary outcome measures Safety, tolerability, viral load reduction, prevention of disease progression, neutralizing antibody generation
Secondary outcomes Pharmacokinetics, immunogenicity, duration of symptoms, hospitalization rates, mortality
Safety monitoring Adverse events, serious adverse events, infusion/injection site reactions, hypersensitivity reactions
Unique applications Use in organ transplantation from COVID-19 positive donors, combination with COVID-19 vaccines

FAQ

  • What is casirivimab and how does it work against COVID-19? Casirivimab is a monoclonal antibody that targets the spike protein of the SARS-CoV-2 virus. It is typically used in combination with another antibody, imdevimab, to help prevent the virus from entering human cells and to neutralize it. This antibody cocktail is designed to treat mild to moderate COVID-19 and potentially prevent infection in high-risk individuals.
  • Who are the main groups being studied in casirivimab clinical trials? Clinical trials are studying casirivimab in various populations, including adults and children with mild to moderate COVID-19, critically ill patients, immunocompromised individuals, and healthy volunteers. Some studies also focus on specific groups like pediatric patients, pregnant women, and organ transplant recipients.
  • What are the primary outcomes being measured in these trials? The primary outcomes vary by study but often include the safety and tolerability of casirivimab, its efficacy in reducing viral load, preventing COVID-19 progression and hospitalization, and its ability to generate neutralizing antibodies. Some trials also assess the pharmacokinetics of the drug and its impact on mortality rates.
  • How is casirivimab administered in these clinical trials? Casirivimab is typically administered intravenously (IV) or subcutaneously (SC), often in combination with imdevimab. The dosage and frequency of administration vary between trials, with some studies comparing different dosing regimens to determine the most effective approach.
  • Are there any potential side effects or safety concerns associated with casirivimab treatment? While casirivimab is generally well-tolerated, clinical trials are monitoring for potential side effects such as infusion-related reactions, injection site reactions, and hypersensitivity reactions. Serious adverse events and the development of anti-drug antibodies are also being closely tracked to ensure the safety of the treatment.

Ongoing Clinical Trials on Casirivimab

  • Study on the Use of Casirivimab, Cilgavimab, Sotrovimab, and Nirmatrelvir for Patients with COVID-19 Infection

    Not recruiting

    1 1 1 1
    Investigated drugs:
    The Netherlands

Glossary

  • Monoclonal antibody: A type of protein made in the laboratory that can bind to substances in the body, including cancer cells. In COVID-19 treatment, monoclonal antibodies like casirivimab are designed to bind to specific parts of the SARS-CoV-2 virus.
  • SARS-CoV-2: The virus that causes COVID-19 (Coronavirus Disease 2019). It belongs to a family of viruses called coronaviruses.
  • Spike protein: A protein on the surface of the SARS-CoV-2 virus that allows it to enter and infect human cells. Many COVID-19 treatments and vaccines target this protein.
  • Pharmacokinetics: The study of how a drug moves through the body, including how it is absorbed, distributed, metabolized, and excreted.
  • Immunogenicity: The ability of a substance to provoke an immune response in the body. In clinical trials, this is often measured by the presence of antibodies against the drug.
  • Anti-drug antibodies (ADA): Antibodies that the body produces against a therapeutic drug. These can potentially reduce the effectiveness of the treatment.
  • Neutralizing antibodies (NAb): Antibodies that bind to a specific part of a pathogen and block its ability to infect cells or replicate.
  • Infusion-related reaction: A side effect that can occur during or shortly after receiving an intravenous medication. Symptoms can range from mild (e.g., fever, chills) to severe (e.g., anaphylaxis).
  • Subcutaneous (SC) administration: A method of giving medication by injecting it under the skin.
  • Intravenous (IV) administration: A method of giving medication directly into a vein using a needle or tube.

References

  1. https://clinicaltrials.gov/study/NCT04425629
  2. https://clinicaltrials.gov/study/NCT05074433
  3. https://clinicaltrials.gov/study/NCT04852978
  4. https://clinicaltrials.gov/study/NCT05081388